Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 4/6 |
Past Performance | 4/6 |
Financial Health | 3/6 |
Dividends | 3/6 |
HYPE3 Stock Overview
Hypera S.A. operates as a pharmaceutical company in Brazil.
Hypera Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | R$42.51 |
52 Week High | R$43.37 |
52 Week Low | R$26.25 |
Beta | 0.51 |
1 Month Change | 7.68% |
3 Month Change | 14.06% |
1 Year Change | 16.24% |
3 Year Change | 33.39% |
5 Year Change | 47.40% |
Change since IPO | 409.10% |
Recent News & Updates
Hypera S.A. (BVMF:HYPE3) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
It's been a good week for Hypera S.A. ( BVMF:HYPE3 ) shareholders, because the company has just released its latest...
Is Hypera (BVMF:HYPE3) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Shareholder Returns
HYPE3 | BR Pharmaceuticals | BR Market | |
---|---|---|---|
7D | -0.6% | -0.9% | 2.8% |
1Y | 16.2% | 9.5% | -18.9% |
Return vs Industry: HYPE3 exceeded the BR Pharmaceuticals industry which returned 8.8% over the past year.
Return vs Market: HYPE3 exceeded the BR Market which returned -18.9% over the past year.
Price Volatility
HYPE3 volatility | |
---|---|
HYPE3 Average Weekly Movement | 5.1% |
Pharmaceuticals Industry Average Movement | 6.2% |
Market Average Movement | 6.0% |
10% most volatile stocks in BR Market | 9.4% |
10% least volatile stocks in BR Market | 2.5% |
Stable Share Price: HYPE3 is not significantly more volatile than the rest of BR stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: HYPE3's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | 9,000 | Breno Pires de Oliveira | https://www.hyperapharma.com.br |
Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, MaxSulid, milgamma, Mioflex – A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands. The company also provides dermo-cosmetics products under the Mantecorp Skincare brands; and consumer health products under the Apracur, Benegrip, Coristina d, Engov, Epocler, Estomazil, and other brands.
Hypera Fundamentals Summary
HYPE3 fundamental statistics | |
---|---|
Market Cap | R$26.90b |
Earnings (TTM) | R$1.64b |
Revenue (TTM) | R$6.65b |
16.4x
P/E Ratio4.0x
P/S RatioIs HYPE3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
HYPE3 income statement (TTM) | |
---|---|
Revenue | R$6.65b |
Cost of Revenue | R$2.44b |
Gross Profit | R$4.21b |
Other Expenses | R$2.57b |
Earnings | R$1.64b |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
Oct 28, 2022
Earnings per share (EPS) | 2.58 |
Gross Margin | 63.32% |
Net Profit Margin | 24.61% |
Debt/Equity Ratio | 79.0% |
How did HYPE3 perform over the long term?
See historical performance and comparisonDividends
2.9%
Current Dividend Yield47%
Payout RatioValuation
Is HYPE3 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Analyst Forecast
Key Valuation Metric
Which metric is best to use when looking at relative valuation for HYPE3?
Other financial metrics that can be useful for relative valuation.
What is HYPE3's n/a Ratio? | |
---|---|
n/a Ratio | 0x |
n/a | n/a |
Market Cap | R$26.90b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 5.1x |
Enterprise Value/EBITDA | 15.3x |
PEG Ratio | 1x |
Price to Earnings Ratio vs Peers
How does HYPE3's PE Ratio compare to its peers?
HYPE3 PE Ratio vs Peers |
---|
Company | PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 28.5x | ||
OFSA3 Ouro Fino Saúde Animal Participações | 10.8x | n/a | R$1.2b |
002603 Shijiazhuang Yiling Pharmaceutical | 32.3x | 24.9% | CN¥37.3b |
603707 Nanjing King-Friend Biochemical Pharmaceutical | 27.7x | 26.6% | CN¥30.9b |
300363 Porton Pharma Solutions | 43.2x | 22.3% | CN¥35.3b |
HYPE3 Hypera | 16.4x | 17.0% | R$26.9b |
Price-To-Earnings vs Peers: HYPE3 is good value based on its Price-To-Earnings Ratio (16.4x) compared to the peer average (28.5x).
Price to Earnings Ratio vs Industry
How does HYPE3's PE Ratio compare vs other companies in the Global Pharmaceuticals Industry?
Price-To-Earnings vs Industry: HYPE3 is expensive based on its Price-To-Earnings Ratio (16.4x) compared to the South American Pharmaceuticals industry average (16.1x)
Price to Earnings Ratio vs Fair Ratio
What is HYPE3's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 16.4x |
Fair PE Ratio | 15.4x |
Price-To-Earnings vs Fair Ratio: HYPE3 is expensive based on its Price-To-Earnings Ratio (16.4x) compared to the estimated Fair Price-To-Earnings Ratio (15.4x).
Share Price vs Fair Value
What is the Fair Price of HYPE3 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: HYPE3 (R$42.51) is trading above our estimate of fair value (R$40.73)
Significantly Below Fair Value: HYPE3 is trading above our estimate of fair value.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
Future Growth
How is Hypera forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?
Future Growth Score
4/6Future Growth Score 4/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
17.0%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: HYPE3's forecast earnings growth (17% per year) is above the savings rate (9.2%).
Earnings vs Market: HYPE3's earnings (17% per year) are forecast to grow faster than the BR market (6.2% per year).
High Growth Earnings: HYPE3's earnings are forecast to grow, but not significantly.
Revenue vs Market: HYPE3's revenue (13.1% per year) is forecast to grow faster than the BR market (5.2% per year).
High Growth Revenue: HYPE3's revenue (13.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: HYPE3's Return on Equity is forecast to be high in 3 years time (20.4%)
Discover growth companies
Past Performance
How has Hypera performed over the past 5 years?
Past Performance Score
4/6Past Performance Score 4/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
10.3%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: HYPE3 has high quality earnings.
Growing Profit Margin: HYPE3's current net profit margins (24.6%) are lower than last year (29.8%).
Past Earnings Growth Analysis
Earnings Trend: HYPE3's earnings have grown by 10.3% per year over the past 5 years.
Accelerating Growth: HYPE3's earnings growth over the past year (11.9%) exceeds its 5-year average (10.3% per year).
Earnings vs Industry: HYPE3 earnings growth over the past year (11.9%) exceeded the Pharmaceuticals industry 10.8%.
Return on Equity
High ROE: HYPE3's Return on Equity (16%) is considered low.
Discover strong past performing companies
Financial Health
How is Hypera's financial position?
Financial Health Score
3/6Financial Health Score 3/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage
Financial Position Analysis
Short Term Liabilities: HYPE3's short term assets (R$6.4B) exceed its short term liabilities (R$3.6B).
Long Term Liabilities: HYPE3's short term assets (R$6.4B) do not cover its long term liabilities (R$7.1B).
Debt to Equity History and Analysis
Debt Level: HYPE3's net debt to equity ratio (64.4%) is considered high.
Reducing Debt: HYPE3's debt to equity ratio has increased from 8.4% to 79% over the past 5 years.
Debt Coverage: HYPE3's debt is well covered by operating cash flow (20.9%).
Interest Coverage: HYPE3's interest payments on its debt are well covered by EBIT (4.2x coverage).
Balance Sheet
Discover healthy companies
Dividend
What is Hypera current dividend yield, its reliability and sustainability?
Dividend Score
3/6Dividend Score 3/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Cash Flow Coverage
2.89%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: HYPE3's dividend (2.89%) is higher than the bottom 25% of dividend payers in the BR market (1.57%).
High Dividend: HYPE3's dividend (2.89%) is low compared to the top 25% of dividend payers in the BR market (7.46%).
Stability and Growth of Payments
Stable Dividend: HYPE3's dividend payments have been volatile in the past 10 years.
Growing Dividend: HYPE3's dividend payments have increased over the past 10 years.
Earnings Payout to Shareholders
Earnings Coverage: With its reasonably low payout ratio (47.5%), HYPE3's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its high cash payout ratio (815.9%), HYPE3's dividend payments are not well covered by cash flows.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
CEO
Breno Pires de Oliveira
no data
Tenure
Mr. Breno Toledo Pires De Oliveira serves as Chief Executive Officer of Hypera S.A. Previously, he served as Chief Financial Officer and Investor Relations Officer at HYPERA S.A. (formerly known as Hyperma...
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Hypera S.A.'s employee growth, exchange listings and data sources
Key Information
- Name: Hypera S.A.
- Ticker: HYPE3
- Exchange: BOVESPA
- Founded: NaN
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: R$26.904b
- Shares outstanding: 632.88m
- Website: https://www.hyperapharma.com.br
Number of Employees
Location
- Hypera S.A.
- Av. Magalhães de Castro, 4800
- 240 Floor
- São Paulo
- São Paulo
- 05676-120
- Brazil
Listings
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2022/08/12 00:00 |
End of Day Share Price | 2022/08/12 00:00 |
Earnings | 2022/06/30 |
Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.